This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (44)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Macular Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Ziad F. Bashshur, MD; Riad N. Ma'luf, MD; Souha Allam, MD; Fadi A. Jurdi, MD; Randa S. Haddad, MD; Baha' N. Noureddin, MD

Arch Ophthalmol. 2004;122:1137-1140.

Objective  To evaluate the efficacy of intravitreal triamcinolone acetonide in the management of persistent macular edema secondary to nonischemic central retinal vein occlusion (CRVO).

Methods  Twenty consecutive patients were selected with a 3- to 4-month history of nonischemic CRVO and persistent macular edema. These patients received a single intravitreal injection of 4 mg of triamcinolone acetonide (40 mg/mL). The follow-up period ranged from 10 to 12 months. The amount of macular edema was assessed by the amount of retinal thickening on clinical examination using the Goldmann contact lens and by the area and intensity of staining on fluorescein angiography. Treated patients were compared with a retrospectively matched group of patients who were managed with observation only.

Main Outcome Measures  Changes in visual acuity and amount of macular edema were assessed in the treated patients and compared with the observation group.

Results  The mean baseline visual acuity in the treatment group was 20/132 vs 20/123 for the observation group (P = .57). After 1 week, the treated group had a mean visual acuity of 20/51. At final follow-up, the treated group had a mean visual acuity of 20/37 while the observation group had a mean visual acuity of 20/110 (P = .001). Sixty percent of treated patients had a final visual acuity of 20/40 or better vs only 20% in the observation group (P = .01). Forty percent of the untreated patients had a final visual acuity worse than 20/200 while none of the treated patients did (P<.001). At final follow-up, 75% of treated patients had complete resolution of macular edema on clinical examination vs only 20% of the untreated patients (P<.001). Two of the treated patients had recurrence of macular edema at 6 months, and 3 had elevated intraocular pressure.

Conclusion  This study shows a treatment benefit from intravitreal triamcinolone in terms of visual acuity and macular edema for nonischemic CRVO.

From the Departments of Ophthalmology, American University of Beirut–Medical Center, Beirut (Drs Bashshur, Ma'luf, Allam, Haddad, and Noureddin), and the Ain Wa Zein Hospital, Shouf (Dr Jurdi), Lebanon. The authors have no relevant financial interest in this article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study
Kriechbaum et al.
Br. J. Ophthalmol. 2008;92:518-522.
ABSTRACT | FULL TEXT  

Triamcinolone Acetonide Inhibits IL-6- and VEGF-Induced Angiogenesis Downstream of the IL-6 and VEGF Receptors
Ebrahem et al.
IOVS 2006;47:4935-4941.
ABSTRACT | FULL TEXT  

The problem of pressure elevation associated with intravitreal triamcinolone.
Conway
Br. J. Ophthalmol. 2006;90:934-935.
FULL TEXT  

The management of retinal vein occlusion: is interventional ophthalmology the way forward?
Shahid et al.
Br. J. Ophthalmol. 2006;90:627-639.
ABSTRACT | FULL TEXT